Levamisole and thymopoietin pentapeptide (TP5) correction of E-rosette depression in man: in vitro and in vivo studies
Several clinical states may show a decrease of the circulating E-rosette forming cells. We observed that the lymphocytes with a reduced E-rosette forming power when incubated in vitro with levamisole either showed an increase in number to the normal values or the E-rosette forming cells did not change. This last group was less frequent and was found in clinical situations compatible with true thymus-dependent T cell depletion (leukaemia, Hodgkin’s disease, LES). Frequently the incubation of lymphocytes with levamisole was promptly followed by a normalization of the E-rosette forming cells.
KeywordsRheumatoid Arthritis Rheumatoid Arthritis Patient Thymic Hormone Immunological Defect Thymic Extract
Unable to display preview. Download preview PDF.
- 1.Di Perri, T., Auteri, A., Laghi Pasini, F. and Mattioli, F. (1978). A weekly oral dose of leva-misole in the treatment of rheumatoid arthritis associated with E-rosette lymphocytes reduction. Eur. J. Rheum. Inflamm., 1,155Google Scholar
- 4.Goldstein, G. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoientin. (unpublished report)Google Scholar
- 5.Verhaegen, H. Comparison of the in vitro effects of thymopoietin pentapeptide and levamisole on peripheral E-rosette formation, (unpublished report)Google Scholar
- 6.Boyum, A. (1968). Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest., 21, (Suppl. 97), 77Google Scholar